Zevra Therapeutics, Inc.
ZVRAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeZevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. Valued at $754.3M, ZVRA is a small-cap name in its sector. The company develops its products through Ligand Activated Technology platform.
Market Cap
$754.3M
Beta
0.85
P/E (TTM)
6.35
P/E (Fwd)
10.68
EPS (TTM)
$2.01
EPS (Fwd)
$1.20
ROE
100.6%
ROA
2.8%
Cash
$200.6M
Total Debt
$1.1M
Free CF
$25.9M
52W Change
0.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $200.6M in cash comfortably exceeding the $1.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $25.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 100.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $10.2M (2022) to $106.5M (2025), reflecting a 948% increase over the period.
With cash comfortably exceeding debt, ZVRA has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Zevra Therapeutics, Inc. and its sector.